(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), included a presentation from Dr. Eugene Pietzak discussing the molecular landscape of non-muscle-invasive bladder cancer. Dr. Pietzak notes that there are relatively well-established molecular subtypes for muscle-invasive bladder cancer, whereas subtypes in non-muscle-invasive bladder cancer are less well-defined. Additionally, the clinical utility of these subtypes is unclear when factoring disease grade and stage.